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Abstract 
Numerous GJB1 gene mutations cause the X-linked form of Charcot-Marie-Tooth disease 
(CMT1X). GJB1 encodes connexin32 (Cx32), which forms trans-myelin gap junctions in 
Schwann cells. Most GJB1 mutations result in loss-of-function mechanisms, supporting the 
concept of gene replacement therapy. However, interactions between delivered wild type and 
endogenously expressed mutant Cx32 may potentially occur in the setting of gene replacement 
therapy. In order to screen for possible interactions of several representative CMT1X mutants 
with wild type Cx32 that may interfere with functional gap junction formation, we established an 
in vitro screening method co-expressing in HeLa cells wild type Cx32 and one of eight different 
Cx32 mutants including A39P, A39V, T55I, R75W, M93V, L143P, N175D and R183S. Some of 
the Golgi-retained mutants hindered gap junction plaque assembly by Cx32 on the cell 
membrane, while co-immunoprecipitation analysis revealed a partial interaction of wild type 
protein with Golgi-retained mutants. Dye transfer studies confirmed that Golgi-retained R75W, 
M93V and N175D but not endoplasmic reticulum-retained T55I had a negative effect on wild 
type Cx32 function. Finally, in vivo intraneural delivery of the gene encoding the wild type Cx32 
in mice bearing either the T55I or R75W mutation on Cx32 knockout background showed that 
virally delivered protein was correctly localized in mice expressing the endoplasmic reticulum-
retained T55I whereas it did not traffic normally in mice expressing the Golgi-retained R75W. 
Thus, certain Golgi-retained Cx32 mutants may interfere with exogenously delivered Cx32. 
Screening for mutant-wild type Cx32 interactions should be considered prior to planning gene 
addition therapy for CMT1X.  
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Introduction 
Charcot-Marie-Tooth (CMT) disease is one of the commonest inherited neurological disorders 
causing progressive degeneration of the peripheral nervous system (1) affecting approximately 1 
in 2500 individuals worldwide. The X-linked form of the disease is one of the most common 
among all types of CMT and is caused by over 400 different mutations in the GJB1 gene 
distributed throughout its length  
(http://hihg.med.miami.edu/code/http/cmt/public_html/index.html#/) (2, 3). The GJB1 gene 
encodes for connexin32 (Cx32), a transmembrane protein which forms gap junctions (GJs) in 
non-compact myelin areas in myelinating Schwann cells and oligodendrocytes (3-5). GJs are 
formed by hexamers of connexin proteins at specialized regions of the plasma membrane 
allowing diffusion of metabolites, ions and electrical impulses (6). The exchange of such essential 
substances between cells or between different compartments of the same cell as in the case of 
myelinating Schwann cells is crucial for preservation of homeostasis, cell survival and function 
(7, 8). CMT1X patients are characterized by demyelination and length-dependent degeneration of 
peripheral nerves which result in progressive distal muscle weakness and wasting, foot 
deformities, areflexia and sensory deficits (9, 10). 
 
Most of the CMT1X mutations are thought to cause loss of Cx32 function as they lead to a 
phenotype that does not differ from the one resulting from complete deletion of the GJB1 gene 
(11-15). Many Cx32 mutants have been studied in vitro and showed abnormal trafficking and 
intracellular retention in the endoplasmic reticulum (ER) and/or Golgi (16-20) followed by 
proteasomal or lysosomal degradation (21). Other mutants may traffick to the membrane, but 
form non-functional channels or channels with altered biophysical properties (22-24). In the case 
of most Cx32 mutants, lack of GJ formation or formation of GJ channels with altered activity 
ultimately leads to loss of GJ function in Schwann cells. This loss of function leads to disturbance 
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of homeostasis not only in Schwann cells and the myelin they form, but also in axons through 
impaired axonal transport and signaling (25-28). 
 
Early in vitro studies indicated that some of Cx32 mutants may also exert dominant negative 
effects on the co-expressed wild type (WT) protein (11, 17) while in vivo models have 
demonstrated a possible interference of endogenously expressed Cx32 mutants with the WT Cx32 
when co-expressed transgenically in the same cells. In particular, the R142W (29) and R75W (12) 
mutants, both retained in the Golgi, but not the ER-retained T55I mutant, reduced the expression 
of co-expressed WT Cx32. The interference of some CMT1X mutants with the WT protein 
occurring in experimental models is not clinically relevant for this X-linked disease at baseline 
given that one of the GJB1 alleles is always inactivated (in women), or only one is present (in 
men). However, it may impair future gene replacement approaches using viral vectors recently 
developed (30, 31) when trying to introduce the WT gene into cells that also express the mutants. 
 
To examine whether a number of different Cx32 mutants could exert any dominant negative 
effect on the co-expressed WT protein we performed an in vitro screening assay. We examined 
the cellular expression of eight different missense mutations associated with CMT1X and their 
possible interactions with the co-expressed WT Cx32 protein, including the ER-retained A39P, 
A39V and T55I and the Golgi-retained R75W, M93V, L143P, N175D and R183S mutants. We 
have also investigated these effects in situ by intrasciatic injections in Cx32 KO mice expressing 
either the T55I or the R75W mutant on a Cx32 KO background, designated as T55I KO and 
R75W KO, respectively, which are representative of the CMT1X mutations. Our results suggest 
that none of the ER-retained mutants impair the correct trafficking of Cx32 hemichannels to cell 
membrane while some of the Golgi-retained mutants show a partial interaction with the virally 
delivered WT Cx32. Thus, they may potentially interfere with future gene delivery in patients 
bearing these mutations. Our study also provides quick screening tools for determining which 
Page 4 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
CMT1X mutants could interact with virally delivered Cx32, prior to planning future gene therapy 
approaches.  
 
 
Results 
 
Golgi-retained CMT1X associated mutants impair the trafficking of WT Cx32 to the cell 
membrane in vitro  
In order to examine whether Cx32 mutants could have a dominant negative effect on co-
expressed WT Cx32 by impeding the normal trafficking to the cell membrane, we studied the 
cellular effects of eight pathogenic missense mutations of Cx32. These were selected because 
their in vitro intracellular retention in the ER (A39P, A39V, T55I), or Golgi (R75W, M93V, 
L143P, N175D and R183S) is representative of most CMT1X mutations (19, 20, 32). The 
localization of each mutant when expressed in communication-incompetent HeLa cells and its 
capacity to form GJ plaques was first examined by performing immunostainings for Cx32 and 
markers of the ER (calnexin), Golgi (58k) (Suppl. Figs. 1 and 2) or the cell membrane (cadherin) 
(Suppl. Fig. 3). Table 1 summarizes the intracellular localization of the Cx32 mutants studied 
and their ability to form GJ plaques.  
 
To assess whether CMT1X mutants could interfere with WT Cx32, we co-expressed by transient 
transfection the WT Cx32 and each of the eight mutants in HeLa cells. We performed 
immunostaining against the flag tag to specifically label the WT Cx32 and myc tag to specifically 
label the mutant Cx32 protein (Fig. 1A-I, Suppl. Fig. 4). Overall, the WT protein appeared to 
form many GJ plaques on the cell membrane of cells co-expressing most CMT1X mutants similar 
to cells expressing the WT Cx32 alone. However, WT protein appeared to be mostly 
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intracellularly retained in cells expressing the R75W mutant, and partly retained in cells 
expressing the M93V and N175D mutants. Counts of the number of GJ-like plaques formed on 
the cell membrane of double expressing cells, demonstrated that most mutants did not cause a 
significant inhibition of the correct trafficking of the WT Cx32 and formation of GJs on the cell 
membrane. However, two of the Golgi retained mutants, the R75W and N175D caused a 
significant reduction of GJ plaques formed by WT Cx32 in co-expressing cells (p<0.001 and 
p=0.00608, respectively) as compared to the number of GJ plaques formed in cells expressing 
only the WT Cx32, suggesting dominant negative effects (Fig. 1J). 
 
To further confirm the expression of the myc-tagged Cx32 mutants and the flag-tagged WT 
Cx32, we examined their levels in double transfected cells by immunoblot analysis. This 
experiment confirmed the presence of both myc-tagged mutants and flag-tagged WT Cx32, 
mostly at comparable levels although in some experiments the level of the mutant or the WT 
protein was higher, without correlation to the presence or not of dominant effects. In non-
transfected HeLa cells there was complete absence of immunoreactivity with either the flag or 
myc antibody, while the absence of a myc band in cells transfected only with the WT protein and 
an empty plasmid, confirmed the expression of the WT protein only, in those cells (Fig. 2). 
 
Golgi-retained CMT1X mutants interact directly with co-expressed WT Cx32  
To further clarify the nature of dominant negative effects of some CMT1X mutants, we assessed 
whether there is any direct interaction between the mutants and the WT protein. Such interaction 
could be a plausible explanation for dominant negative effects since during the folding and 
oligomerization of connexins into hexamers taking place after exiting the ER in the ER - cis 
Golgi network (33, 34), mutant connexins could participate in the same hexamer oligomerizing 
with WT protein monomers. This interaction could prevent the trafficking of the entire hexamer 
including WT Cx32 to the cell membrane and impair the formation of functional GJ channels. In 
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this experiment, we co-transfected HeLa cells with the WT protein fused to a flag tag along with 
the myc-tagged mutants and performed co-immunoprecipitations. This analysis showed that none 
of the ER-retained mutants interacted with the WT protein, while three of the Golgi-retained 
mutants, the R75W, M93V and N175D, revealed a partial interaction (Fig. 3A). Nevertheless, the 
interaction level of the R75W, M93V and N175D with the WT protein was lower compared to 
the WT-WT interactions (Fig. 3B). Notably, when we co-expressed the WT flag-tagged protein 
with the WT myc-tagged Cx32, a strong band on the immunoblot confirmed their full interaction, 
as expected from the formation of hexamers before reaching the cell membrane.    
 
Functional impairment of GJ connectivity in cells co-expressing WT Cx32 with the R75W, 
M93V, and N175D but not with the T55I mutant 
Given the interference of some Golgi-retained Cx32 mutants with the normal trafficking of the 
co-expressed WT Cx32 shown with the immunocytochemistry and the direct interaction shown 
by immunoprecipitation, we then asked whether these interactions could also affect the function 
of GJ channels formed by the WT Cx32. To investigate this possibility, we examined four 
representative mutants, the Golgi-retained R75W, M93V and N175D mutants, which showed 
interaction with the WT protein, and the ER-retained T55I that did not interact. These mutations 
were cloned along with the dsRED fluorescent marker as a reporter gene and co-expressed with 
the WT protein which was traced by the eGFP. Possible impairment of GJ channel function was 
assessed by Lucifer yellow scrape loading assay with quantification of coupled cells co-
expressing WT Cx32 and each of the four mutants (Fig. 4A-P). Our results demonstrated no 
significant functional impairment of GJ connectivity in cells co-expressing WT Cx32 and the ER-
retained T55I mutant (p>0.05), whereas a significant reduction of coupled cells was observed in 
the presence of the R75W (p=0.0001), M93V (p=0.00055) and N175D (p=0.0063) mutants, 
compared to the coupled cells expressing only the WT Cx32 (Fig. 4Q).  
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Thus, our in vitro results suggest a direct interaction of at least three of the Golgi-retained 
mutants with the WT Cx32 when co-expressed in the same cells, leading to reduced formation of 
GJ plaques on the cell membrane by WT Cx32, and reduced cell coupling, while such 
interactions were not observed with ER-retained mutants. 
 
Intraneural GJB1 gene delivery leads to WT Cx32 expression and correct localization at 
paranodal non-compact myelin areas in T55I KO but not in R75W KO sciatic nerves  
In order to confirm the correct trafficking of the WT Cx32 in the presence of a mutant protein in 
myelinating Schwann cells in vivo, we performed intraneural injections of the LV.Mpz-GJB1 
(full) or LV.Mpz-eGFP (mock) vector directly into sciatic nerves of 2-mo-old T55I KO and 
R75W KO mice, as well as simple Cx32 KO (Gjb1-null) mice, as controls. The human GJB1 
gene expression is driven specifically in myelinating Schwann cells by the rat myelin protein zero 
(Mpz) promoter (30, 35). Cx32 expression and localization was analyzed 4 weeks post injection 
by immunostaining of teased fibers from injected nerves. Double immunostaining for Cx32 and 
the paranodal marker Caspr revealed Cx32 immunoreactivity only in the perinuclear cytoplasm of 
Schwann cells in T55I KO nerves injected with the mock vector, representing the endogenous 
mutant Cx32 (Fig. 5A). In contrast, T55I KO nerves injected with the full vector (LV.Mpz-GJB1) 
showed in addition to the perinuclear mutant Cx32 immunoreactivity, also correct Cx32 
localization at paranodal non-compact myelin areas where Cx32 is normally expressed (4), 
representing the virally expressed WT Cx32 (Fig. 5B). The expression of virally delivered WT 
Cx32 in T55I KO nerve fibers was similar to the expression obtained in control Cx32 KO mice 
that did not express any Cx32 endogenously, injected with the same vector. On the other hand, 
Cx32 immunoreactivity was absent at most paranodal myelin areas in the R75W KO sciatic nerve 
fibers injected with the full vector (Fig. 5C). Additionally, mutant Cx32 was highly expressed in 
the perinuclear Schwann cell cytoplasm, indicating retention of the R75W mutant, likely together 
with the exogenously expressed WT protein.  
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Counts from randomly selected paranodal areas revealed that there was no significant difference 
in the percentage of Cx32-positive paranodal areas between T55I KO and Cx32 KO nerves 
injected with the full vector (p>0.5; n=50 nodal areas per mouse, n=8 mice per genotype), 
indicating that the T55I mutant does not inhibit the correct trafficking of the virally delivered WT 
Cx32 and correct localization at paranodal areas in vivo. In contrast, a significant reduction of 
Cx32-positive paranodal areas was found in full vector injected R75W KO nerve fibers compared 
to full vector injected Cx32 KO nerves (p=0.00011; n=50 nodal areas per mouse, from n=4 mice), 
confirming that the R75W mutant likely exerts dominant negative effect on the virally delivered 
WT Cx32 protein causing largely cytoplasmic retention in myelinating Schwann cells in vivo 
(Fig. 5D), in keeping with our in vitro results. 
 
 
Discussion 
This study provides insights into possible interactions between Cx32 mutants associated with 
CMT1X and the co-expressed WT Cx32, with important implications for future gene therapy 
approaches to treat patients suffering from this disease. Our in vitro and in vivo studies show a 
differential effect of several Cx32 mutants, with Golgi-retained mutants showing the highest 
likelihood for dominant negative effects. Methods developed in this study could provide a 
screening tool for rapid testing of further CMT1X mutants for possible interactions when gene 
replacement therapy is considered. 
 
Previous studies have shown that Cx32 mutants often accumulate intracellularly, localizing 
predominantly in the ER or Golgi with or without the formation of rare GJ-like plaques (17, 19, 
20). As misfolded proteins could be toxic for the cell, they are degraded efficiently via lysosomal 
or proteasomal protein degradation pathways (21). In keeping with previous studies in which the 
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expression of most of these mutants has been examined, we show here that the A39P, A39V and 
T55I mutants were retained primarily in the ER whereas the R75W, M93V, L143P, N175D and 
R183S mutants co-localized with the 58k Golgi marker. Some of the mutants showed additional 
localization in cytoplasmic vesicles (M93V, N175D, R183S). HeLa cells expressing only the WT 
Cx32, which served as a positive control, exhibited distinct and large GJ plaques at the 
intracellular boundaries of apposed membranes while Cx32 expression was also sometimes 
detectable as a punctuate pattern in the cytoplasm due to its high expression. The M93V and 
R183S mutants exhibited mostly cytoplasmic pattern with rare GJ plaques at intercellular contact 
regions compared to the WT Cx32, whereas the A39P, A39V, T55I, R75W and L143P and 
N175D exhibited exclusively a cytoplasmic expression pattern. The CMT1X mutants examined 
here are therefore representative of most other Cx32 mutations reported and previously expressed 
in vitro or in vivo (12, 19, 20, 29). 
 
In the present study, we have examined the localization of eight Cx32 gene mutants discovered in 
CMT1X patients and investigated their possible interference with the WT protein. For this 
purpose, each mutant was co-expressed with the WT protein in HeLa cells and assessed for GJ-
like plaque formation on the cell surface. Our immunofluorescence data revealed that when co-
expressed with the R75W and N175D mutants, the WT protein was partially retained 
intracellularly and failed to reach the cell membrane. Furthermore, co-immunoprecipitation assay 
revealed that the three Golgi-retained mutants R75W, M93V and N175D exhibited a direct 
interaction with the WT protein whereas the remained five mutants did not demonstrate such 
interaction. Any differences in the expression levels of the mutant and WT proteins did not affect 
our immunostaining results, as in our analysis we included individual cells co-expressing both the 
WT and mutant protein.  
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Moreover, our functional assay tracing the diffusion of the GJ-permeable tracer Lucifer yellow in 
cells co-expressing the WT protein with either the ER-retained T55I or the Golgi-retained R75W, 
M93V and N175D mutants showed that there was a significant reduction of GJ-coupled cells in 
R75W, M93V and N175D expressing cells, as compared to cells expressing only the WT protein. 
This indicated a reduced formation of functional GJ channels, whereas in the case of the T55I 
mutant, Lucifer yellow was transferred to adjacent GJ-coupled cells as expected, suggesting 
physiological GJ permeability. Further dominant negative effects between co-expressed WT and 
mutant Cx32 could occur at the functional level once hemichannels with mutant-WT hexamers 
reach the membrane (18). Although we have not directly tested this possibility in this study, our 
dye transfer analysis in the scrape loading assay indicates that the M93V mutant, which reaches 
the cell membrane co-localizing with WT Cx32 as shown by our immunocytochemistry results, 
could actually impair functional GJ formation and cell connectivity if it participates in the same 
hemichannels as WT Cx32. 
 
Analysis of possible interactions between WT and mutant Cx32 in vivo, demonstrated that the 
R75W mutant, which also exhibits an interaction with the WT protein in vitro, interferes with the 
WT protein and inhibits its trafficking to the paranodal areas of Schwann cells, where it is 
normally localized (4). This is in keeping with our previous observations when the R75W mutant 
was transgenically expressed in WT mice and caused impaired expression of endogenous WT 
Cx32 as well as mild neuropathy on a WT background (12). In contrast, the T55I mutant did not 
affect the physiological routing of the WT protein to paranodal areas, as compared to Cx32 KO 
mice that were injected with the same vector. Thus, our in vivo findings correlate with the in vitro 
results showing an interaction of the WT Cx32 at least with the Golgi-retained R75W mutant and 
not with the ER-retained T55I. 
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The pattern of interference of the Golgi but not ER-retained mutants with WT Cx32 as shown by 
this study, is probably attributed to the fact that the ER-retained Cx32 mutants, considered as 
incorrectly folded proteins, are rapidly degraded in the proteasomes by the ER-associated 
degradation process (19, 21, 36). In contrast, mutants which can overcome the ER quality control 
system are further transported to the Golgi, where connexin oligomerization into hexamers takes 
place (37) before transport to the membrane. In the Golgi apparatus, such mutants may have a 
direct physical interaction with WT Cx32 molecules during oligomerization events through 
participation in the same hexamer as shown by our co-immunoprecipitation results. Ultimately, 
this interaction could disrupt the trafficking of the WT protein to the cell membrane resulting in 
reduced formation of functional GJ channels. Oligomerization of compatible subunits into 
hexameric hemi-channels is subject to a strictly regulated process (38, 39). Specific signals could 
possibly be responsible for the determination of WT-mutant connexin polypeptides compatibility, 
in analogy to the hetero-oligomerization of different connexin isoforms which is based on 
specific intrinsic signals. Even a single point mutation could prevent the binding of modifiers that 
assist the correct folding of a polypeptide and facilitate its interaction with other monomers 
during oligomerization, or change its surface structure resulting in subunit incompatibility (33). 
This could be the case for the two Golgi-retained L143P and R183S mutants that did not show 
any interaction with the WT protein. 
 
One limitation of our study is that the in vitro HeLa cell system cannot fully reproduce the in vivo 
conditions, and variations in WT/mutant expression levels may influence some of the results. 
Although we only examined here a small fraction of the large number of known CMT1X 
mutations, they are representative of the most common cell expression patterns. Nevertheless, this 
in vitro screening provides a valuable technique to rapidly evaluate the expected efficacy of gene 
replacement therapy in patients harboring specific CMT1X mutations. Another concern is that the 
expression rates of the WT and mutant proteins were similar in most in vitro experiments 
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resulting in partial interactions of some Golgi-retained mutants, whereas gene replacement 
approaches studied so far in vivo resulted in lower expression levels of virally delivered Cx32 
compared to the endogenous physiological expression levels (30, 31). Likewise, if patients have a 
higher level of the endogenously expressed interfering mutant compared to virally delivered WT 
Cx32 dominant negative effects may be maximized abolishing any possible therapeutic benefit. 
However, this possibility does not limit the validity of our results obtained in vitro as they 
correlate highly with our in vivo findings in terms of identifying mutants interacting with WT 
Cx32. Finally, even though scrape loading assays have been widely used to study GJ function, 
more sensitive methods such as electrophysiological studies could be used to evaluate GJ 
conductance more accurately in the setting of WT/mutant Cx32 interactions (40, 41). 
 
Based on the findings of this study that some of the Golgi-retained mutants interfere with the WT 
Cx32, gene therapy approaches using gene addition may have to be modified for patients 
harboring mutations with dominant-interfering effects. In such cases, gene editing approaches to 
correct the specific mutation (42) or RNA interference could be used to downregulate the 
expression of the mutant allele prior to gene addition of the WT gene (43), or allele-specific 
silencing (44, 45) should be attempted simultaneously with WT gene addition. For patients 
harboring ER-retained mutants that do not interfere with WT Cx32, our results suggest that gene 
addition approaches could be directly performed. The development of such therapeutic 
approaches has been also supported by animal studies demonstrating restoration of the WT Cx32 
protein expression in Schwann cells either by intrathecal (31) or intraneural injections (30) in 
GJB1-null mice.  
 
In conclusion, this study has delineated the possible interactions of eight representative missense 
GJB1 mutations with the WT Cx32 protein in vitro by investigating intracellular trafficking, 
direct interactions and GJ function. Moreover, in vivo studies confirmed the in vitro findings for 
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two representative mutants. Taken together, the results of this study suggest that the examination 
and elucidation of possible interactions between the WT Cx32 and each mutant may assist future 
gene therapy for CMT1X. The extremely large number of mutations reported in the GJB1 gene to 
date and their variable cellular-molecular mechanisms mandates a mutation-tailored therapeutic 
strategy for each individual patient with CMT1X following a prior screening of the mutant 
effects. 
 
 
Materials and methods 
 
WT and mutant Cx32 expression constructs  
For the in vitro co-expression and co-immunoprecipitation experiments, the WT Cx32 was fused 
to a flag tag in order to examine any possible interactions with the myc-tagged mutants. To insert 
the flag sequence in the pEGFP-N1 plasmid carrying the GJB1 ORF, the plasmid was double 
digested with appropriate enzymes (BamHI/NotI) to remove the eGFP sequence. Specifically 
designed primers carrying the entire flag sequence with sticky ends (Primer #1: 5 ’-GAT CCC 
GAC TAC AAG GAC GAC GAC GAC AAG TAAGC -3’ and Primer #2:  5’ –GGC CGC TTA 
CTT GTC GTC GTC GTC CTT GTA GTC GG -3’) were used and the PCR product was ligated 
into the pEGFP-N1 plasmid. Correct assembly of the expression cassettes was confirmed by 
restriction digest mapping and direct sequencing. 
 
To distinguish the WT from mutant Cx32 in co-expression experiments, the GJB1 mutations 
A39V, A39P, M93V, L143P and R183S were introduced into the WT human Cx32 cDNA 
(cloned into the pEGFP-N1-Myc plasmid) by polymerase chain reaction using the QuikChange II 
XL Site-Directed Mutagenesis Kit (Stratagene, USA). For the generation of the mutants, 
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specifically designed oligonucleotide primers were used to introduce the point mutation as shown 
on Table 2. In the PCR reaction, the high fidelity Pfu Ultra DNA polymerase (2.5 U) was used 
and the PCR products were digested with the DpnI restriction enzyme to eliminate the parental 
supercoiled DNA. The DpnI-treated DNA was used to transform the XL10-Gold ultracompetent 
bacterial cells. DNA isolation was performed from single colonies and the GJB1/Cx32 sequence 
for each mutant was confirmed by direct sequencing. The T55I and R75W mutations were taken 
from previously described constructs (12) while the N175D mutation (obtained from Dr. Donglin 
Bai, University of Western Ontario) was directionally cloned into the pEGFP-N1-Myc plasmid 
using the XhoI/BamHI sites.  
 
Lentiviral expression constructs  
For the scrape loading assay, the GJB1 gene along with the downstream internal ribosome entry 
site (IRES) and eGFP sequence, was PCR amplified from the pIRES2-EGFP-CX32 plasmid 
using specifically designed primers that introduce the AgeI and SalI restriction sites (Primer #1:  
5’- AAA CCG GTG GCA GGA TGA ACT GGA CAGG -3’ and Primer #2:  5’- ACG CGT 
CGA CCC GTT ACT TGT ACA GCT CGT -3’). The PCR product was run on a gel to confirm 
the correct size band and purified using the Qiagen Gel Extraction Kit (Qiagen, Hilden). The 
DNA fragment was then directionally cloned into the 2
nd
 generation  
pCCLsin.PPT.hPGK.GFP.pre lentiviral transfer vector (30) (gift from Dr. Carsten Lederer) under 
the expression of the ubiquitous PGK promoter, following digestion with the AgeI and SalI 
restriction enzymes. Correct assembly of the expression cassette was confirmed by direct 
sequencing.   
 
For the in vivo intrasciatic injections, the LV.Mpz-GJB1 expression cassette was produced based 
on the same lentiviral vector. For this purpose, the human PGK promoter was replaced by the rat 
Mpz promoter which is expressed specifically in myelinating Schwann cells (35). The human 
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GJB1 ORF was inserted downstream of the Mpz promoter using appropriate restriction enzymes, 
along with the IRES and eGFP, serving as a reporter gene. An LV.Mpz-eGFP mock vector 
cassette without the GJB1 ORF was also cloned to be used as a negative control. Correct 
expression cassettes were confirmed by direct sequencing of the ORFs. 
 
Lentiviral vector production and titration   
Recombinant lentiviruses were produced by co-transfection of the transfer vector with the helper 
plasmids (CMV∆R8.74, pRSV-Rev, and pMD2-VSVG [vesicular stomatitis virus G protein]) in 
HEK 293T cells using the calcium phosphate co-precipitation method as previously described 
(30). Approximately 24 hours prior the transfection, a total of 5 x 10
6
 293T cells were seeded in 
10 cm plates in Iscove Modified Dulbecco’s Medium (IMDM) supplemented with 10%  heat 
inactivated Fetal Bovine Serum (FBS), penicillin and streptomycin (100 U/ml) and glutamine. 
The plates were incubated O/N in a humidified atmosphere with 5% CO2 at 37
o
C. One hour prior 
to transfection, the culture medium in the plates was removed and replaced with fresh medium. 
The plasmid DNA mix was prepared by combining 2µg of the envelope plasmid pMD2-VSVG, 
20µg of the packaging plasmid CMV∆R8.74, 10µg of the pRSV-Rev and 20µg of the transfer 
vector plasmid. Then, 521µl of 0.1x TE/dH2O (2:1) was added to the mixture followed by 
addition of 60µl 2.5M CaCl2 for 5 minutes. The precipitate was formed by dropwise addition of 
600µl 2x HSBSs solution (HEPES-buffered saline) to the mixture while vortexing at full speed. 
The precipitate was immediately added to the cells and the medium was replaced after 12 hours 
with fresh medium containing 1mM sodium butyrate. After two days, lentivirus was harvested, 
cleared by low-speed centrifugation and filtered through a 0.45 µm-pore-size filter. The filtered 
supernatant was then concentrated using the Lenti-X Concentrator (Clontech, USA) reagent 
followed by a short incubation and centrifugation. Viral titers were determined by a HIV-1 Gag 
p24 enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription 
polymerase chain reaction (RT-PCR) for EGFP. 
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Cell culture and transfections 
Communication-incompetent HeLa cells were cultivated in a humidified atmosphere containing 
5% CO2 at 37
o
C in low-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBCO, 
Invitrogen) supplemented with 10% FBS, antibiotics-antimycotics (penicillin/streptomycin) at a 
concentration of 100 µg/ml and 10% non-essential amino acids. Cell cultures were routinely 
subcloned by trypsinization and medium was changed every 2-3 days. Cell transfections were 
performed using the cationic lipid based Lipofectamine LTX with PLUS reagent transfection 
system (Invitrogen) when the cells reached approximately 70% confluency. For transient 
transfection, plasmid DNA (WT or mutant) along with the PLUS reagent and lipofectamine LTX 
were incubated separately in OptiMem (Reduced-Serum Medium) and then mixed for 15 minutes 
at RT. The DNA-lipid complex was added dropwise to the cells that were incubated in 4-chamber 
slides or 6-well plates. The following day, the transfection reagent was replaced with fresh 
medium.  
 
Immunocytochemistry 
Transfected cells were plated on glass slides reaching 90% confluency, fixed in 4% 
paraformaldehyde (PFA), washed in PBS and permeabilized in acetone for 10 min at -20
o
C. The 
slides were then immersed twice in PBS to remove residual acetone and the cells were blocked in 
blocking solution (5% BSA with 0.1% Triton-X) for 1 hour at RT. Primary antibodies diluted in 
blocking solution including rat anti-flag (1:100, Biolegend), goat anti-Cx32 (1:300, Santa Cruz) 
and mouse anti-myc (1:300, Santa Cruz), anti-cadherin (1:500, Abcam), anti-calnexin (1:50, 
Abcam) and anti-58k (1:50, Abcam) were used and incubated overnight at 4
o
C. The following 
day, cells were washed 3x in PBS followed by addition of appropriate fluorescein- and 
rhodamine-conjugated secondary antibodies for 1 hour at RT (1:500, Jackson ImmunoResearch). 
The slides were then washed in PBS and cell nuclei were stained with 4-6-diamidino-2-
Page 17 of 42 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
phenylindole (DAPI). At the final step, the slides were mounted with Dako fluorescent Mounting 
Medium and images were visualized with a fluorescence microscope using Axiovision software 
(Carl Zeiss MicroImaging). To confirm the cellular localization of WT and mutant Cx32 in co-
expressing cells, we also performed confocal microscopy using a Leica DMR microscope (Leica 
Microsystems). 
 
For quantification of GJ plaque formation in transfected cells as an indication of Cx32 trafficking 
to the cell membrane, we counted the number of GJ plaques per cell in n=50 cells for each 
experiment/mutation where mutant and WT Cx32 were co-expressed, compared to the number of 
GJ plaques formed in cells expressing only the WT Cx32.  
 
Immunoblot analysis 
Protein samples were subjected to 10% SDS gel electrophoresis and transferred onto a PVDF 
membrane (GE Healthcare Life Sciences) by a wet transfer unit using 1x transfer buffer (25 mM 
Tris, 192 mM Glycine, 20% methanol). Non-specific sites were blocked with 5% skimmed milk 
powder diluted in 0.1% PBS-Tween 20 (PBS-T) for 1 hour at RT. Membranes were incubated at 
4
o
C overnight with rat anti-flag (1:500, Biolegend), mouse anti-myc (1:200, Cell Signaling) and 
mouse anti-β-tubulin (1:3000, Developmental Studies Hybridoma Bank). The following day, the 
membranes were washed 3x with PBS-T and were further incubated with anti-rat or anti-mouse 
secondary antibodies conjugated to horseradish peroxidise (HRP) (1:3000, Jackson 
ImmunoResearch) for 1 hour at RT. After washing, the bands were visualized using the enhanced 
chemiluminescence system (ECL, GE Healthcare Bio-Sciences). Band intensities were calculated 
using Tinascan software.  
 
Immunoprecipitation assay 
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Co-transfected cells (with WT Cx32-flag tagged and mutant Cx32-myc tagged) were harvested in 
ice-cold RIPA containing protease inhibitors (Roche). After harvesting, the cells were passed 
through a 25-gauge needle twice and spinned down at high speed for 30 min. The supernatant 
was used for the immunoprecipitation assay. Rat anti-flag (3 µg, Biolegend) was mixed with 
Protein G-Dynabeads (Invitrogen) magnetic particles for 45 min to coat the particles. The anti-
Rat IgG-coated particles were then incubated overnight at 4
o
C with 1000 mg of whole cell lysate. 
The following day, the particles were isolated with a ceramic magnet and then washed with cold 
0.2% PBS-Tween 20, re-suspended in SDS-PAGE sample buffer and analysed by immunoblot 
using the mouse myc antibody (1:500, Santa Cruz). For quantification, Cx32 band intensity for 
each mutant was measured with Tinascan software and compared to the band intensity of the 
positive control, expressed as ratio, from two independent experiments. 
 
Scrape loading assay 
In order to examine the functional consequences of co-expressing mutants with WT Cx32 using 
the scrape loading method, we used an expression vector with dsRED as a reporter gene 
specifically for the mutants. The GJB1/Cx32 mutations T55I and M93V were excised from the 
pREP9 vector by double digestion with the BamHI and KpnI enzymes and were directionally 
cloned into the PSLN1180 plasmid. The entire ORF of the GJB1/Cx32 mutations was 
subsequently taken out by double digestion with the AgeI and EcoRI enzymes and cloned into the 
PQCXIX plasmid precisely upstream of the IRES.dsRED sequence. The GJB1/Cx32 mutations 
R75W and N175D were PCR amplified from previously used constructs using specifically 
designed primers that introduced the AgeI and EcoRI restriction sites (Primer #1:  5’- AAA CCG 
GTG GCA GGA TGA ACT GGA CAGG -3’ and Primer #2:  5’- CCG GAA TTC CGG TTA 
CAG GTC CTC CT-3’). The PCR products were then digested and cloned into the PQCXIX 
plasmid, following digestion with the AgeI and EcoRI restriction endonucleases. Correct 
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assembly of the expression cassettes was confirmed by direct sequencing of the GJB1 ORF for all 
constructs.  
 
HeLa cells expressing the WT Cx32 after infection with the LV.PGK-GJB1.eGFP vector, were 
seeded on 6-well plates to reach approximately 70% confluency when transfected with the 
selected Cx32 mutants and about 90-100% confluency on the day of the scrape loading. In this 
experiment, cells were gently rinsed 3x with PBS without calcium or magnesium and incubated 
with Lucifer yellow fluorescent stain (Sigma, MW: 457.25), a molecule that is transferred 
through GJs, diluted in PBS at a final concentration 100µM. Immediately after the addition of 
Lucifer yellow, cells were scraped drawing horizontal and vertical lines using a scalpel blade and 
incubated in the dark for 10 minutes. Afterwards, cells were washed 3x with Hank´s Balanced 
Salt Solution (HBSS) containing calcium and magnesium to stop GJ communication and 
coverslips were used to cover the cells. Pictures were captured using a Nikon Eclipse TE2000-U 
microscope with a Nikon digital Camera DXM 1200F.  
 
To quantify the formation of functional GJ channels, we counted the number of coupled cells co-
expressing the WT and mutant Cx32 that were also positive for the Lucifer yellow fluorescence 
(excluding cells on the scrape line), indicating dye transfer through GJs from neighboring cells. 
For each mutation n=20 cells were counted from 3 independent experiments. The results were 
expressed as percentage of coupled cells compared to the positive control experiment where cells 
expressed the WT Cx32 only. 
 
Experimental animals 
Two month-old C57BL/6 male and female mice expressing on a Gjb1-null background either the 
T55I (T55I KO) (n=8) or the R75W mutation (R75W KO) (n=4) described elsewhere (12) were 
used for intraneural injections of the WT GJB1 gene cloned into a lentiviral vector, as previously 
Page 20 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 
 
described (30). Mice were injected in the sciatic nerve with the mock vector on one side and with 
the full vector on the contralateral side. All experimental procedures were conducted in agreement 
with animal care protocols approved by the Cyprus Government’s Chief Veterinary Officer and 
according to EU guidelines (EC Directive 86/609/EEC). 
 
Intraneural Injection of the Lentiviral Vector  
The mice were initially anesthetized and surgically incised close to the sciatic nerve area to gain 
access to the nerve. Pulled glass micropipettes were used to inject the nerve immediately distal to 
the sciatic notch using a microinjector (FemtoJet; Eppendorf, Hamburg, Germany). For each 
nerve, ten microliters of either full or mock vector were injected and 5/0 silk suture (Silkam; 
Braun, Melsungen, Germany) was used promptly to close the wounds. Mice were sacrificed 4 
weeks after gene delivery and the expression of Cx32 was examined by immunostaining of teased 
nerve fibers. The lentiviral stock titers were between 3.6×10
11 
(full vector) and 4×10
12
 (mock 
vector) viral particles/ml. 
 
Immunohistochemistry 
For immunofluorescence staining of sciatic nerve teased fibers, mice were firstly anesthetized 
with Avertin in accordance to approved protocols and transcardially perfused with saline solution 
(NaCl 0.9%) followed by 4% PFA diluted in 0.1 M Phospate buffer (PB). The bilateral sciatic 
nerves were detached from the knee to the spinal cord and divided into proximal, middle and 
distal segments. All segments were teased under a stereoscope and teased fibers were transferred 
onto slides, air dried overnight and frozen at -20
o
C until used. Teased fibers were permeabilized 
in acetone for 10 min at -20
o
C and washed 3x in PBS, then blocked in blocking solution (5% 
BSA with 0.5% Triton-X) for 1 hour at RT. Primary antibodies were added and incubated 
overnight at 4
o
C, including rabbit anti-Cx32 (1:50, Sigma-Aldrich) and mouse anti-Caspr (1:100, 
gift from Prof. Steven Scherer, University of Pennsylvania). The following day, the slides were 
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washed in PBS and incubated with fluorescein- and rhodamine-conjugated secondary antibodies 
for 1 hour at RT (1:500, Jackson ImmunoResearch). Cell nuclei were stained with DAPI and 
slides were mounted with Dako fluorescent Mounting Medium. Images were captured with a 
fluorescence microscope using Axiovision software (Carl Zeiss MicroImaging).   
 
Quantification of Cx32 positive nodal areas (defined as the ones showing Cx32 immunoreactivity 
in paranodal myelin areas) out of 50 randomly selected nodes was performed in multiple teased 
fiber preparations from all mice that received the full vector and statistical analysis was 
conducted by comparing the number of Cx32-positive nodes in the T55I KO and R75W KO 
nerves to the number of positive nodes in simple Cx32 KO mice. 
 
Statistical analysis 
All statistical comparisons were performed using the unpaired two-sided Student’s t-test and 
Microsoft Excel software (Microsoft, Redmond, WA). Values were presented as mean ± standard 
deviation (SD).  A value of p<0.05 was considered statistically significant. 
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Figure legends 
Figure 1: Co-expression of WT Cx32 with CMT1X mutants. Images of immunostained HeLa 
cells co-expressing the flag-tagged wild type (WT) Cx32 along with each of the myc-tagged 
A39P, A39V, T55I, R75W, M93V, L143P, N175D and R183S mutants as indicated (A-H) or the 
myc-tagged WT protein as control (I). Anti-myc antibody (green) recognizes mutant Cx32, 
whereas anti-flag antibody (red) recognizes WT Cx32. Cell nuclei are counterstained with DAPI 
(blue). Most mutants show intracellular localization, either exclusively, or with additional 
membrane expression and gap junction (GJ) plaque formation (M93V, R183S). The co-expressed 
WT Cx32 shows variable cellular localization and GJ formation on the cell membrane. In the 
presence of the ER-retained A39P, A39V and T55I mutants (A-C) WT Cx32 appears to form 
normally GJ plaques (open arrowheads) and shows no intracellular immunoreactivity. In the 
presence of Golgi-retained mutants WT Cx32 shows intracellular retention and reduced GJ 
formation, most prominently with co-expressed R75W mutant (D), but also with M93V, L143P 
and N175D mutants (E-G). In cells co-expressing mutants that reach the cell membrane (M93V, 
R183S) WT Cx32 and mutant Cx32 are partly co-localized in GJ-like plaques (E, H). J: 
Quantification of GJ plaque formation by the WT protein (number of membrane GJ plaques per 
cell) in n=50 cells for each co-expressed mutant revealed that the R75W and N175D mutants 
significantly reduce the correct trafficking of the WT Cx32 to the cell surface (p<0.001 and 
p=0.00608, respectively) as compared to the number of GJ plaques formed by the WT Cx32 
alone. The remaining five mutants did not cause significant changes in this experiment. 
***p<0.001, **p<0.01, Scale bar=10 µm. 
 
Figure 2: Immunoblot analysis demonstrating the expression levels of mutant and WT Cx32 
in HeLa cells. Lysates of HeLa cells transiently co-transfected to express each of the myc-tagged 
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Cx32 mutants as indicated along with the flag-tagged WT Cx32, were immunoblotted using 
antibodies recognizing the myc or flag tags on the proteins. An empty plasmid was also co-
transfected with the flag-tagged WT Cx32 as a negative control for the myc antibody. Note the 
absence of any bands in untransfected HeLa cells in the first lane, which was used as a negative 
control. Tubulin blot is shown below as a loading control. The expression levels of most mutants 
were similar to WT Cx32 with some also showing lower or higher levels compared to the WT 
protein, as indicated by the intensity of myc and flag bands, respectively. 
 
Figure 3: Some of the Golgi-retained CMT1X mutants interact directly with the WT Cx32. 
Co-immunoprecipitation (co-IP) of the flag-tagged WT Cx32 protein co-expressed in HeLa cells 
with myc-tagged Cx32 mutants as indicated using a flag antibody followed by immunoblot with a 
myc antibody to assess the interactions between the WT and mutant proteins (A). HeLa cells 
expressing the flag-tagged WT protein only, served as a negative control. The co-expression of 
the myc and flag-tagged WT proteins (WT+WT) served as a positive control for the experiment. 
Five of the mutants showed no co-IP with the WT protein, while the Golgi-retained R75W, 
M93V and N175D mutants revealed a partial interaction, as compared to the positive control. The 
results of the N175D mutant are from a different gel. Quantification of band intensity reflecting 
the percentage of mutant-WT compared to WT-WT (considered as 100%) direct interaction from 
two independent experiments is shown in (B).  
 
Figure 4: Impaired WT Cx32 GJ channel function in cells co-expressing the R75W, M93V 
and N175D but not the T55I mutant. These are representative immunofluorescence images of 
scrape-loaded (with Lucifer yellow) HeLa cells that co-express the WT Cx32 along with the T55I 
(A-D), R75W (E-H), M93V (I-L) or the N175D (M-P) mutants. Panels A, E, I and M show the 
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cells expressing the WT Cx32 indicated by GFP green fluorescence, panels B, F, J and N show 
the cells expressing the mutants indicated by dsRed red fluorescence, while panels C,G, K and O 
show cells that contain Lucifer yellow. Overlap images are shown in Panels D, H, L and P. In 
cells co-expressing the T55I mutant and the WT Cx32, Lucifer yellow diffuses into adjacent cells 
(white arrows), demonstrating that cellular GJ connectivity is not abolished. In contrast, cells co-
expressing WT Cx32 and the R75W, M93V or the N175D mutant show reduced dye transfer to 
adjacent cells indicating impaired formation of functional GJs. Q: Quantification of cellular GJ 
connectivity (% of mutant-WT Cx32 double expressing cells showing dye transfer to adjacent 
cells from n=20 double expressing cells in each experiment) shows significant reduction of 
coupled cells in the presence of the R75W (66.7±2.9% coupled cells, p=0.0001), M93V 
(76.7±2.9% coupled cells, p=0.00055) and N175D (73.3±7.6% coupled cells, p=0.0063) mutants 
but not in the presence of the T55I mutant (88.3±5.8%, p>0.05) compared to cells expressing WT 
Cx32 alone (97.3±2.1%). Scale bar=20µm. 
 
Figure 5: The Golgi-retained R75W mutant but not the ER-retained T55I mutant interferes 
with the expression of virally delivered WT Cx32 in vivo. These are images from sciatic nerve 
teased fibers of LV.Mpz-eGFP (mock) vector injected T55I KO nerves as negative control (A), as 
well as LV.Mpz-GJB1 (full) vector injected T55I KO (B) or R75W KO (C) nerves, 
immunostained with antibodies to Cx32 (red) and paranodal marker Caspr (green). Cell nuclei are 
stained with DAPI (blue). In the higher magnification images, asterisks indicate Schwann cell 
nuclei showing also the cytoplasmic/perinuclear expression of the retained T55I and R75W 
mutants (red). WT Cx32 immunoreactivity is normally localized in the paranodal areas of non-
compact myelin in the T55I KO mice (arrows in B) but not in the R75W KO nerve fibers (C) or 
in mock injected T55I KO nerves (A). D: Quantification of nodal myelin areas expressing Cx32 
shows similar rates of paranodal localization of virally delivered WT Cx32 in T55I KO fibers 
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(34±7.6% Cx32-positive paranodal areas, p>0.05) compared to Cx32 KO (Gjb1-/-) (36±5.5%), 
whereas in most R75W KO fibers injected with the full vector WT Cx32 does not reach the 
paranodal areas (10±2.3%, p=0.00011). Scale bar=30 µm. 
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Supplementary figures 
 
Supplementary Figure 1: Cellular expression of CMT1X mutants co-localizing with cell 
markers. These are representative immunofluorescence images of transfected HeLa cells 
expressing different Cx32 mutants as indicated, double immunostained for Cx32 (red) and either 
the endoplasmic reticulum (ER) marker calnexin (A-C) or the Golgi marker 58k (D-H) (both in 
green) as indicated, to clarify the intracellular localization of each mutant. Cell nuclei are 
counterstained with DAPI (blue). The A39P, A39V and T55I mutants are co-localized with the 
ER marker calnexin, whereas the R75W, M93V, L143P, N175D and R183S mutants are mostly 
co-localized with the Golgi marker 58k. Scale bar=10 µm. 
 
Supplementary Figure 2: Cellular expression of CMT1X mutants. These are 
immunofluorescence images of transfected HeLa cells expressing different Cx32 mutants as 
indicated, double immunostained for Cx32 (red) and either the Golgi marker 58k (A-C) or the ER 
marker calnexin (D-H) (both in green) as indicated, to clarify the intracellular localization of each 
mutant. Cell nuclei are counterstained with DAPI (blue). The A39P, A39V and T55I mutants do 
not colocalize with the Golgi marker 58k, while the R75W, M93V, L143P, N175D and R183S 
mutants are mostly restricted to the Golgi compartment and do not co-localize with the ER 
marker calnexin. Scale bar=10 µm. 
 
Supplementary Figure 3: CMT1X mutants show complete or partial intracellular retention. 
These are immunofluorescence images of HeLa cells expressing Cx32 mutants (A-H) or the WT 
protein (I) as indicated, immunostained with the membrane marker cadherin (green) and Cx32 
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(red). Cell nuclei are counterstained with DAPI (blue). All mutants (A-H) are retained 
intracellularly as most of their immunoreactivity is inside of the cadherin immunoreactivity which 
marks the cell membrane without co-localization, in contrast to the WT protein which is mostly 
co-localized with cadherin on the cell membrane forming GJ plaques (I). However, some of the 
mutants show additional localization on the cell membrane, including the M93V and R183S 
(open arrowheads). Scale bar=10 µm.  
 
Supplementary Figure 4: Confocal analysis of co-expressed WT Cx32 with CMT1X 
mutants. These are confocal images of immunostained HeLa cells co-expressing the flag-tagged 
wild type (WT) Cx32 along with each of the myc-tagged A39P, A39V, T55I, R75W, M93V, 
L143P, N175D and R183S mutants as indicated (A-H). Anti-myc antibody (green) recognizes 
mutant Cx32, whereas anti-flag antibody (red) recognizes WT Cx32. In the presence of the ER-
retained A39P, A39V and T55I mutants (A-C) WT Cx32 appears to form normally GJ plaques 
(open arrowheads) and shows no intracellular immunoreactivity. In the presence of Golgi-
retained mutants, WT Cx32 shows intracellular retention and reduced GJ formation, most 
prominently with co-expressed R75W mutant (D), but also with M93V, L143P and N175D 
mutants (E-G). In cells co-expressing mutants with intracellular localization that also reach the 
cell membrane (M93V, R183S), WT and mutant Cx32 are partly co-localized in GJ-like plaques 
(E, H). Scale bar=2 µm. 
 
 
 
  
Page 34 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
35 
 
Table 1: Cx32 mutants studied and in vitro cellular expression pattern  
Mutation Cellular localization Gap junctions 
formed 
Previous 
studies 
A39P (c.115 G>C) Endoplasmic reticulum None (19) 
A39V (c.116 C>T) Endoplasmic reticulum None (19) 
T55I (c.164 C>T)                              Endoplasmic reticulum None (19) 
R75W (c.223 C>T) Golgi None (20) 
M93V (c.277 A>G) Golgi  Many (19) 
L143P (c.428 T>C) Golgi None (32) 
N175D (c.523 A>G)   Golgi None unpublished 
R183S (c.547 C>A) Golgi Some (19) 
 
 
  
Page 35 of 42 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
36 
 
Table 2: Polymerase Chain Reaction (PCR) Primers Used for Site-Directed Mutagenesis 
*The highlighted base is the one altered in the underlined codon 
  
Mutation Primers* 
M93V Sense: 5’-CTCTCCTCGTGGCCGTGCACGTGGCTCAC -3’ 
Antisense: 5’-GTGAGCCACGTGCACGGCCACGAGGAGAG – 3’ 
A39V Sense: 5’-CATGGTGCTGGTGGTGGTTGCAGAGAGTGTGTGGG –3’ 
Antisense:5’-CCCACACACTCTCTGCAACCACCACCAGCACCATG -3’ 
A39P Sense: 5’-CATGGTGCTGGTGGTGCCTGCAGAGAGTGTGTG-3’ 
Antisense: 5’-CACACACTCTCTGCAGGCACCACCAGCACCATG-3’ 
R183S Sense: 5’-GGACTGCTTCGTGTCCAGCCCCACCGAGAAAAC-3’ 
Antisense: 5’-GTTTTCTCGGTGGGGCTGGACACGAAGCAGTCC –3’ 
L143P Sense: 5’-CGTGGTGTTCCGGCCGTTGTTTGAGGCCG –3’ 
Antisense: 5’-CGGCCTCAAACAACGGCCGGAACACCACG -3’ 
Page 36 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
37 
 
Abbreviations 
BSA: Bovine serum albumin 
CMT: Charcot–Marie–Tooth disease 
CMT1X: X-linked form of Charcot–Marie–Tooth disease type 1 
Cx32: Connexin 32 
DAPI: 4-6-diamidino-2-phenylindole 
eGFP: Enhanced green fluorescent protein 
GJ: Gap junction 
GJB1: Gap junction beta-1 (gene) 
ER: Endoplasmic reticulum 
KO: Knockout 
PBS: Phosphate buffered saline 
PFA: Paraformaldehyde 
SDS: Sodium dodecyl sulphate 
WT: Wild type 
 
Page 37 of 42 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 1: Co-expression of WT Cx32 with CMT1X mutants. Images of immunostained HeLa cells co-
expressing the flag-tagged wild type (WT) Cx32 along with each of the myc-tagged A39P, A39V, T55I, 
R75W, M93V, L143P, N175D and R183S mutants as indicated (A-H) or the myc-tagged WT protein as 
control (I). Anti-myc antibody (green) recognizes mutant Cx32, whereas anti-flag antibody (red) recognizes 
WT Cx32. Cell nuclei are counterstained with DAPI (blue). Most mutants show intracellular localization, 
either exclusively, or with additional membrane expression and gap junction (GJ) plaque formation (M93V, 
R183S). The co-expressed WT Cx32 shows variable cellular localization and GJ formation on the cell 
membrane. In the presence of the ER-retained A39P, A39V and T55I mutants (A-C) WT Cx32 appears to 
form normally GJ plaques (open arrowheads) and shows no intracellular immunoreactivity. In the presence 
of Golgi-retained mutants WT Cx32 shows intracellular retention and reduced GJ formation, most 
prominently with co-expressed R75W mutant (D), but also with M93V, L143P and N175D mutants (E-G). In 
cells co-expressing mutants that reach the cell membrane (M93V, R183S) WT Cx32 and mutant Cx32 are 
partly co-localized in GJ-like plaques (E, H). J: Quantification of GJ plaque formation by the WT protein 
(number of membrane GJ plaques per cell) in n=50 cells for each co-expressed mutant revealed that the 
R75W and N175D mutants significantly reduce the correct trafficking of the WT Cx32 to the cell surface 
(p<0.001 and p=0.00608, respectively) as compared to the number of GJ plaques formed by the WT Cx32 
alone. The remaining five mutants did not cause significant changes in this experiment. ***p<0.001, 
**p<0.01, Scale bar=10 µm.  
Fig. 1  
180x161mm (300 x 300 DPI)  
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Figure 2: Immunoblot analysis demonstrating the expression levels of mutant and WT Cx32 in HeLa cells. 
Lysates of HeLa cells transiently co-transfected to express each of the myc tagged Cx32 mutants as 
indicated along with the flag tagged WT Cx32, were immunoblotted using antibodies recognizing the myc or 
flag tags on the proteins. An empty plasmid was also co-transfected with the flag tagged WT Cx32 as a 
negative control for the myc antibody. Note the absence of any bands in untransfected HeLa cells in the first 
lane, which was used as a negative control. Tubulin blot is shown below as a loading control. The expression 
levels of most mutants were similar to WT Cx32 with some also showing lower or higher levels compared to 
the WT protein, as indicated by the intensity of myc and flag bands, respectively.  
Fig. 2  
86x33mm (300 x 300 DPI)  
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Figure 3: Some of the Golgi-retained CMT1X mutants interact directly with the WT Cx32. Co-
immunoprecipitation (co-IP) of the flag-tagged WT Cx32 protein co-expressed in HeLa cells with myc-tagged 
Cx32 mutants as indicated using a flag antibody followed by immunoblot with a myc antibody to assess the 
interactions between the WT and mutant proteins (A). HeLa cells expressing the flag-tagged WT protein 
only, served as a negative control. The co-expression of the myc and flag-tagged WT proteins (WT+WT) 
served as a positive control for the experiment. Five of the mutants showed no co-IP with the WT protein, 
while the Golgi-retained R75W, M93V and N175D mutants r vealed a partial interaction, as compared to the 
positive control. The results of the N175D mutant are from a different gel. Quantification of band intensity 
reflecting the percentage of mutant-WT compared to WT-WT (considered as 100%) direct interaction from 
two independent experiments is shown in (B).  
Fig. 3  
86x56mm (300 x 300 DPI)  
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Figure 4: Impaired WT Cx32 GJ channel function in cells co-expressing the R75W, M93V and N175D but not 
the T55I mutant. These are representative immunofluorescence images of scrape-loaded (with Lucifer 
yellow) HeLa cells that co-express the WT Cx32 along with the T55I (A-D), R75W (E-H), M93V (I-L) or the 
N175D (M-P) mutants. Panels A, E, I and M show the cells expressing the WT Cx32 indicated by GFP green 
fluorescence, panels B, F, J and N show the cells expressing the mutants indicated by dsRed red 
fluorescence, while panels C,G, K and O show cells that contain Lucifer yellow. Overlap images are shown in 
Panels D, H, L and P. In cells co-expressing the T55I mutant and the WT Cx32, Lucifer yellow diffuses into 
adjacent cells (white arrows), demonstrating that cellular GJ connectivity is not abolished. In contrast, cells 
co-expressing WT Cx32 and the R75W, M93V or the N175D mutant show reduced dye transfer to adjacent 
cells indicating impaired formation of functional GJs. Q: Quantification of cellular GJ connectivity (% of 
mutant-WT Cx32 double expressing cells showing dye transfer to adjacent cells from n=20 double 
expressing cells in each experiment) shows significant reduction of coupled cells in the presence of the 
R75W (66.7±2.9% coupled cells, p=0.0001), M93V (76.7±2.9% coupled cells, p=0.00055) and N175D 
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(73.3±7.6% coupled cells, p=0.0063) mutants but not in the presence of the T55I mutant (88.3±5.8%, 
p>0.05) compared to cells expressing WT Cx32 alone (97.3±2.1%). Scale bar=20µm.  
Fig. 4  
180x229mm (300 x 300 DPI)  
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Figure 5: The Golgi-retained R75W mutant but not the ER-retained T55I mutant interferes with the 
expression of virally delivered WT Cx32 in vivo. These are images from sciatic nerve teased fibers of 
LV.Mpz.eGFP (mock) vector injected T55I KO nerves as negative control (A), as well as LV.Mpz.GJB1 (full) 
vector injected T55I KO (B) or R75W KO (C) nerves, immunostained with antibodies to Cx32 (red) and 
paranodal marker Caspr (green). Cell nuclei are stained with DAPI (blue). In the higher magnification 
images, asterisks indicate Schwann cell nuclei showing also the cytoplasmic/perinuclear expression of the 
retained T55I and R75W mutants (red). WT Cx32 immunoreactivity is normally localized in the paranodal 
areas of non-compact myelin in the T55I KO mice (arrows in B) but not in the R75W KO nerve fibers (C) or 
in mock-injected T55I KO nerves (A). D: Quantification of nodal myelin areas expressing Cx32 shows similar 
rates of paranodal localization of virally delivered WT Cx32 in T55I KO fibers (34±7.6% Cx32-positive 
paranodal areas, p>0.05) compared to Cx32 KO (Gjb1-/-) (36±5.5%), whereas in most R75W KO fibers 
injected with the full vector WT Cx32 does not reach the paranodal areas (10±2.3%, p=0.00011). Scale 
bar=30 µm.  
Fig. 5  
180x102mm (300 x 300 DPI)  
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